May 14th 2024
The duration of neoadjuvant chemotherapy may be optimized via MRI guidance for the treatment of hormone receptor-negative/HER2-positive breast cancer.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Dr. Schover on the Web-Based Intervention "Tendrils" for Breast Cancer Survivors
March 28th 2014Leslie R. Schover, PhD, clinical psychiatrist, professor, behavioral science, The University of Texas MD Anderson Cancer Center, discusses the web-based intervention Tendrils: Sexual Renewal and Motherhood after Cancer.
Phone Application Helps Endometrial and Breast Cancer Survivors Lose Weight
March 28th 2014Early-stage overweight endometrial and breast cancer survivors had moderate success in lowering their body mass index (BMI) and waste circumference after using the web and smart phone/tablet–based weight loss application "Lose It!"
Anastrozole Found to Prevent Breast Cancer in High-Risk Postmenopausal Women
March 21st 2014Findings from the International Breast Cancer Intervention Study II (IBIS II) examining the efficacy of the aromatase inhibitor anastrozole as a breast cancer preventive show that the oral agent provided significant benefit to postmenopausal women deemed at high risk
Select Older Patients Can Avoid Radiation After Breast-Conserving Surgery
March 18th 2014A subgroup of older breast cancer patients may be able to forgo radiation therapy (RT) after breast-conserving surgery if they are treated with hormonal therapy and considered to be at low risk for breast cancer recurrence
Exercise Reduces Joint Pain in Breast Cancer Patients Treated With Aromatase Inhibitors
March 13th 2014A new study reported at the 2013 San Antonio Breast Cancer Symposium shows that a prescribed exercise program reduces joint pain in breast cancer survivors taking aromatase inhibitors (AIs), with pain reductions observed at all levels of exercise.
Preventive Prophylactic Oophorectomy Should be performed by age 35 for women with BRCA1 mutations.
February 25th 2014International researchers from seven countries conducted a prospective study to determine risk reduction of ovarian, fallopian tube, or peritoneal cancer in women with a BRCA1 or BRCA2 mutation after oophorectomy and examine other factors, such as impact of this procedure on mortality and five year survival.
Dr. Neumayer on Patient Education Following a Breast Cancer Diagnosis
February 11th 2014Leigh A. Neumayer, MD, professor of surgery, University of Utah School of Medicine, co-director of the multidisciplinary team treating breast cancer at Huntsman Cancer Institute, discusses patient education following a breast cancer diagnosis.
Perioperative Breast MRI Does Not Lower Recurrence Risk for Early-Stage Patients
January 13th 2014Patients with ductal carcinoma in situ (DCIS) who received an MRI added to mammography before or immediately after receiving a lumpectomy did not experience an improvement in the rate of disease recurrence
Mammogram Study Provides Rationale for Expanding Screening Programs
January 7th 2014Most deaths from breast cancer occur in women who have not been regularly screened and whose tumors are diagnosed at a median age 49 years, confirming the need for the greater use of annual mammography in younger women
Genetic Experts' Views Shift on Testing, Prophylactic Surgery
May 28th 2013The decision about whether to get tested for a genetic mutation that may predispose a person to certain cancers is a difficult one for many patients to make. Even more difficult for mutation carriers is deciding whether to undergo a prophylactic surgical procedure.
Counseling BRCA, Lynch Carriers on Prophylactic Oophorectomy
May 8th 2013Due to the high lifetime risk of ovarian cancer and the poor ovarian cancer surveillance options available, women who carry BRCA1 or BRCA2 mutations are advised to remove their ovaries and fallopian tubes by age 40 or when childbearing is complete.